Wash Post: The federal government has cancelled a $100 million study that was going to examine the new generation of drugs known as aromatase inhibitors, which seemed to be more effective at reducing the risk of breast cancer. It is unusual to cancel a long-planned study but the National Cancer Institute said it couldn’t justify the study because of questions about the drug’s safety. The study was going to give raloxifene or an aromatase inhibitor to 12,800 women at high risk for breast cancer at 500 sites in the U.S and Canada and follow them for five years.
New York Times: A new study says that thousands of women with breast cancer—about 8,000 a year in the U.S. --aren’t offered genetic testing that might identify that her breast cancer was inherited from her father. In families where there are few older sisters and aunts, the gene’s path may be hidden.
Published On: June 20, 2007